PLSEPulse Biosciences, Inc.
Price
+206%1YEnd-of-day closes, not the intraday tick.
Mostly good, one thing to check: growth
Quality strong, nothing alarming, growth fading, the market with it.
We are a novel ablation company committed to health innovation using our patented Nano-pulse Stimulation (“NPS”) technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to nonthermally clear or kill targeted cells. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation (“nsPFA”) technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Pulse Biosciences, Inc. (PLSE) reported revenue of $434K in Q2 2026 (quarter ended Jun 30, 2026). That came with a gross margin of 37% and net loss of $25M. For the full year FY2025, revenue was $350K and net income −$73M. Its largest product in Q2 2022 (quarter ended Jun 30, 2022) was System Products at $209K, 79% of the disclosed total, well ahead of Cycle Units Products at 21%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 7, 2026On October 7, 2026, Pulse Biosciences, Inc. (the “Company”) announced that it had achieved its enrollment target of 164 evaluable patients in its NANOPULSE-AF clinical study evaluating the Company’s nPulse™ Cardiac Catheter System for the treatment of atrial fibrillation (the “Study”)Other event · Form 8-K
- Sep 15, 2026On September 15, 2026, Pulse Biosciences, Inc. (the “Company”) entered into an equity distribution agreement (the “Sales Agreement”) with Mizuho Securities USA LLC (“Mizuho”) as sales agent, pursuant to which the Company may offer and sell, from time to time, through Mizuho, shares of the Company’s common stock, par …Material agreement entered · Form 8-K
- Sep 15, 2026On September 15, 2026, Pulse Biosciences, Inc. (the “Company”) announced completion of patient enrollment in its PRECISE-BTN clinical study evaluating the Company’s nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of symptomatic benign thyroid nodules (the “Study”)Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2022 · $265.0KThe company’s own SEC segment disclosure.
- System Products$209.0K79%
- Cycle Units Products$56.0K21%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Instruments & Supplies
Ranks #21 of 21 by RyuScore